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Sjögren’s syndrome (SS) is a systemic autoimmune disease characterised by chronic 
inflammation of the salivary and lacrimal glands, resulting in complaints of xerostomia and 
keratoconjunctivitis sicca in about 95% of the patients. These symptoms are frequently 
accompanied by extraglandular manifestations, and 85% of the patients suffer from severe 
fatigue.(1) Furthermore, the presence of SS has a large impact on health related quality of 
life (HR-QoL), employment and disability.
Yet, no causal systemic treatment is available in SS and therefore only symptomatic 
treatment can be given. Currently, biological agents have been introduced in various systemic 
autoimmune diseases including rheumatoid arthritis (RA) and systemic lupus erythematosus 
(SLE). However, no biological agent has been approved thus far for the treatment of SS, 
but several phase II and III studies have recently been completed or are currently being 
conducted. The effect of treatment with biological agents is aimed at reducing disease 
activity and to slow down progression of SS.
In the research described in this thesis the impact of SS on quality of life has been 
evaluated, the different approved and experimental treatment options have been reviewed, 
existing and new tools to evaluate treatment were assessed and treatment results with anti-
CD20 monoclonal antibodies (rituximab) are presented. 
Chapter 2 describes HR-QoL, employment and disability in patients with primary (pSS) 
and secondary (sSS) SS, compared to data available from the general Dutch population. 
A questionnaire was sent to the total cohort of SS patients within the University Medical 
Center Groningen that is seen for scheduled follow-up. 195 out of 235 patients (83%) 
responded. The results revealed that SS has a large impact on HR-QOL, employment and 
disability as reflected by lower Short Form-36 (SF-36) scores (measuring subjective well-
being), lower employment rates and higher disability rates in SS patients when compared to 
the general Dutch population. In addition, physical functioning, bodily pain and general health 
were worse in sSS than in pSS patients. The results of this trial underscore the necessity for 
the development of causal treatment for SS.
Therefore, in chapter 3 an overview is given of the trials performed in SS with biological 
agents up to 2006 and future perspectives are presented. The gain in knowledge regarding 
the cellular mechanisms of T and B lymphocyte activity in the pathogenesis of SS and the 
current availability of various biological agents (anti-TNF-α, IFN-α, anti-CD20, and anti-
CD22) have resulted in new possibilities for therapeutic intervention. In SS, various phase I 
and II studies have been performed to evaluate these biologicals. Currently, B cell directed 
therapies, and especially the use of anti-CD20 monoclonal antibodies, have been shown to 
be more promising than T cell related therapies. In the near future a large role for treatment 
with biologicals for SS is expected. Larger phase II and III trials are necessary to confirm 
these first promising results. 
In general, evaluation of a new treatment modality requires well defined and usable tools 
to evaluate the effect of treatment. Chapter 4a gives a general overview of existing tools 
for evaluation of treatment for diseases affecting salivary glands. Assessments of salivary 
gland function (sialometry, sialochemistry) and histopathological examination of salivary 

















assess disease progression and to evaluate treatment. More general tools are subjective 
questionnaires (e.g., visual analogue scale (VAS) scores, Multidimensional Fatigue Inventory 
(MFI) score and SF-36) and serological parameters.
Chapter 4b describes the development of a new evaluation tool, the genomic and 
proteonomic profile of whole saliva. In the study described in this chapter, the profiles for 
SS patients were compared to healthy age and sex matched controls. This preliminary study 
indicated that both glandular and whole saliva from pSS patients contain molecular signatures 
that reflect damaged glandular cells and an activated immune response. Whole saliva was 
shown to be more useful in SS diagnostics than parotid and submandibular/sublingual saliva. 
The candidate proteonomic and genomic biomarkers found in whole saliva may improve the 
clinical detection of pSS once they have been further validated in a larger group of patients. 
The evaluation tools described in chapter 4 were used in evaluating treatment with 
rituximab, described in chapter 5. In chapter 5a a study is described assessing the efficacy 
and safety of (re)treatment of SS patients with rituximab after extended follow-up (mean 
follow-up 57 weeks) of B cell depletion therapy. Included were 8 early pSS patients and 
7 pSS patients with a mucosa-associated lymphoid tissue (MALT)-type lymphoma (MALT/
pSS). Rituximab was effective for 6-9 months in pSS patients and, probably, even longer 
in MALT/pSS patients. Retreatment of 5 pSS patients resulted in a comparable beneficial 
effect as observed after the first course. Development of serum sickness-like disorder in 
27% of pSS patients indicated that higher doses of corticosteroids might be needed during 
rituximab treatment.
In chapter 5b the results of histopathological evaluation of parotid tissue after rituximab 
treatment were correlated with clinical results of parotid function in order to evaluate 
rituximab treatment on a more fundamental level. Sequential parotid biopsies before and 12 
weeks after rituximab treatment in pSS patients demonstrated histopathological evidence 
of reduced glandular inflammation and redifferentiation of lymphoepithelial duct lesions to 
regular striated ducts as a putative morphological correlate of increased parotid flow and 
normalization of salivary sodium content. These histopathological findings underline the 
efficacy of B cell depletion and prove the potential for glandular restoration in SS. This 
study was performed as a pilot in the 5 pSS patients that received retreatment described 
in chapter 5b. Analysis of larger groups of patients biopsied before and after rituximab 
treatment are necessary to confirm these first results.
Based on these promising results, a randomized double-blind placebo-controlled trial 
was performed (chapter 5c). In this trial 30 pSS patients were included, of which 20 were 
treated with rituximab, while 10 patients received placebo. All 30 patients received an 
additional dose of corticosteroids in order to prevent the development of side effects. In 
this trial, B cell depletion led to improvement of objective and subjective parameters of 
disease activity. Salivary function improved, fatigue diminished, extraglandular manifestations 
improved. Most improvements were seen 12 to 36 weeks after treatment. These promising 
results suggest that a larger phase III trial should be performed in order to receive approval 
for rituximab treatment of SS.
Although SS is considered to be a T lymphocyte mediated disease, there are more and more 
signs that the role of the B cells should not be underestimated.(2) The description of the 
cases described in chapter 6 has deepened our insight into the B cell component of SS. 







localized cutaneous amyloidosis. The databases of 3 amyloidosis centres (Italy; University of 
Pavia, Germany; University of Heidelberg and the Netherlands; Medical Center Groningen) 
were searched in order to find this rare combination. It was likely that AL amyloid was the 
actual type in all 8 patients, which is an immunoglobulin light chain associated amyloid, locally 
produced by a light chain-restricted plasma cell population in the skin. The combination of 
cutaneous amyloid and SS appeared to be a distinct disease entity reflecting a particular and 
benign part of the polymorphic spectre of lymphoproliferative diseases related to SS.
General discussion
Sjögren syndrome: is there a need for treatment and which treatment is available?
SS is known to affect patients’ physical, psychological and social functioning (3), but the 
impact of SS on health-related quality of life (HR-QOL), and especially on employment 
and disability, has not been studied extensively before. However, this information is 
necessary to interpret the burden of the disease and also to gain insight into the necessity 
for treatment. Therefore, the analysis described in chapter 2 was performed. Comparable 
to other autoimmune diseases, SS has a large impact on HR-QOL, employment and 
disability as reflected by lower SF-36 scores and employment rates, and higher disability 
rates when compared with the general Dutch population. The impact on socioeconomic 
status described in chapter 2 justifies further research on biologicals in the treatment of SS, 
even though these treatments are expensive and intensive. In addition, the overview of the 
reports on biological treatment for SS (chapter 3) revealed that anti-CD20 (rituximab) is 
the most promising biological agent so far.(4-6) The results of some of therapies targeting 
TNF-α (infliximab, etanercept and adalimumab) and IFN-α were also promising in phase I 
and II studies, but in larger placebo controlled randomized trials results were disappointing. 
So, although the first results with rituximab seem promising, also regarding this biological 
larger placebo controlled trials are needed to confirm these promising results (see section 
on rituximab treatment). Moreover, as rituximab is a chimeric anti-CD20 agent that has 
the inherent hazard of inducing serum sickness, humanized anti-CD20 (ocrelizumab) that 
more recently has become available might, in potential, be an even more promising B cell 
therapy. Another promising B cell directed therapy is anti-CD22 (epratuzumab). This agent 
seemed to be effective in a small open-label trial, although to a lesser extent than rituximab 
as it only partially depletes B cells.(7). Other potential targets for biological therapy include 
cytokines such as IL-6 and BlyS (BAFF), interferons, adhesion molecules and chemokines. 
No trials in SS have yet been performed with these biological therapies, however. 
Which evaluation tools are useful?
With the increasing number of trials performed aiming to treat SS, there is a growing need 
for more specific assessment parameters to monitor treatment effects, both subjectively 
and objectively. For studies on intervention in SS, especially evaluation of the parotid gland 
might be of use. Assessment of parotid secretory function (sialometry), composition of 
parotid saliva (sialochemistry) and histological examination of parotid gland tissue (repeated 
incisional biopsies) are routinely used in our setting to evaluate the effect of an intervention 
therapy as a function of time. Also scintigraphy, functional MRI, PET scans and ultrasound 
can be used repeatedly in evaluating the parotid gland. The diagnostic accuracy of the 

















evaluation. More general tools, but very valuable in evaluating intervention in SS, are 
subjective questionnaires (e.g. VAS scores, MFI scores and SF-36) and serological parameters 
such as rheumatoid factor and immunoglobulin levels, and B cell counts in the case of B cell 
depletion therapy.
Furthermore, both glandular and whole saliva are easy to obtain and the first results 
from studies on genomics and proteonomics (chapter 4b) showed valuable results. As a 
continuation of this study, a validation paper reported on the discovery of highly specific 
autoantibody biomarkers for pSS using protein microarray technology.(8) If the genomics 
and proteonomics can be used in the future as diagnostic tools for SS and as tools for 
monitoring the effect of treatment, for example rituximab treatment, in depth saliva 
analysis might even replace more invasive diagnostic tools such as parotid biopsies, PET and 
scintigraphy. 
What about rituximab treatment?
Based on the promising results described in the review (chapter 3) and in the open label 
phase II study (chapter 5a and 5b), a randomised, placebo-controlled trial with rituximab 
was performed (chapter 5c). The results of the latter trial confirmed the promising results 
of the phase II trials, but, also some criticism was raised related to the treatment of early 
pSS patients without extraglandular manifestations with this biological. Because the long 
term (side-)effects of treatment with biological agents in SS are not known yet, some SS 
experts suggest to use treatment only for those SS patients with severe extraglandular 
manifestations(9;10). However, we observed that patients with remaining glandular function 
at the time of diagnosis benefit more from rituximab treatment than patients without any 
function left. Thus, in our opinion patients with active disease, as reflected by high levels of 
IgG and rheumatoid factor, increasing complaints of fatigue, and/or sicca complaints and/or 
swelling of the parotid gland (but still having glandular function), are the preferred patients 
to be treated with rituximab. Besides this group of early patients, also patients with severe 
extraglandular manifestations may benefit significantly from treatment. Of course, the long-
term side effects of rituximab treatment have to be thoroughly investigated in larger phase 
III trials before implementation of this biological as therapy for SS.
In contrast to patients with lymphoma or RA treated with rituximab, serum sickness 
or serum sickness-like adverse events are more frequently reported in SS patients, with 
a rate between 6% and 27%. (chapter 3) This initially unexpected finding may be due to 
the use of different co-medication. Patients with RA and systemic lupus erythematosus 
(SLE) usually receive higher doses of steroids or concomitantly immunosuppressive drugs 
as compared with SS patients, which may prevent certain adverse events. In addition, 
RA and SLE patients often have been treated with a wide range of medication (including 
biological agents) before receiving treatment with rituximab, whereas SS patients are far 
more medication-naïve at the time of rituximab treatment. We also observed in the trial 
described in chapter 5c, as well as in our pilot trial, that patients who developed serum 
sickness were more likely to have an active, early and progressive form of the disease.(6) 
It is possible that such patients are more prone to develop serum sickness; however, such 
patients might also be the ones that most likely benefit from rituximab therapy. Another 
possibility is that SS patients may be more prone to develop and deposit immune complexes 
because of hypergammaglobulinaemia and/or cryoglobulinemia.(4) Consequently, because 
of the inherent risk of developing serum sickness (like) disease, we decided to increase 







Table 1 Number of patients who actually received placebo or rituximab and the estimation of the patients and 
the physicians.
Patient Patient Physician 1 Physician 1 Physician 2 Physician 2
True False True False True False
Rituximab (20) 16 4 18 2 17 3
Placebo (9) 7 2 8 1 8 1
Total (29) 23 (79%) 6 (21%) 26 (90%) 3 (10%) 25 (86%) 4 (14%)
one patient developed serum sickness-like disease (5%), which is considerably lower than 
the incidence reported in our open-label study (27%).(6) Furthermore, HACA (human 
antichimeric antibodies) development, which occurred in 27% of patients in our open-label 
trial, was not found in the only patient who developed serum sickness-like disease. Based on 
these findings, we would recommend administering 100 mg methylprednisolone immediately 
prior to each infusion of rituximab. The oral regimen of prednisolone in the days following 
each infusion differ between different trials and should be explored in future trials. The 
administration of higher doses of prednisolone in the days following infusion, such as is 
performed during lymphoma treatment, should also be considered, because most lymphoma 
patients are, as SS patients, medication-naïve at time of rituximab treatment, and no serum 
sickness has been reported in these patients.
Retreatment with rituximab resulted in a positive effect comparable to that of the first 
treatment with this biological (chapter 5a). Therefore, offering patients maintenance therapy 
with rituximab infusions every 6 to 9 months may be a reasonable approach. Advantages of 
maintenance therapy might be a reduction or even arrest of disease progression and better 
quality of life for a long period. A threat might be the, so far unknown, long term side 
effects of repeated B cell depletion. The timing of retreatment could be based on return of 
symptoms, however, retreatment just before return of symptoms would even be better. A 
prediction model based on the results of our placebo controlled trial, showed that levels of 
rheumatoid factor could be a good predictor for return of subjective symptoms such as dry 
mouth and fatigue (unpublished results). However, these preliminary results were based on 
20 pSS patients and, therefore, in future trials, attention should be paid to the correlation 
between objective and subjective symptoms. We even like to pose that such a correlation 
might provide a base for selecting the most optimal retreatment schedule. Probably, for 
each patient an individual time scheme has to be made because we observed that the time 
period in which rituximab reduced SS related symptoms/complaints differed considerably 
between patients. 
The dose of rituximab that patients should receive during maintenance treatment should 
also be investigated. Based on the positive results after 2 infusions of 375mg/m² (which 
is in total about 1000 mg) as reported by Devauchelle et al.(5), probably even only one 
infusion of 1000 mg could be sufficient. Another issue concerns the question which group 
of patients should be offered retreatment. In RA patients, results of trials on retreatment 
of non-responders to first treatment are not conclusive. Thurlings et al. (11) reported that 
only responders to the first treatment benefit from retreatment, while Vital et al. reports 
that retreatment of non-responders before circulating plasma cells return to baseline 
levels enhances B cell depletion and results in a better clinical response.(12) With respect 

















and validated and results of retreatment of both responders and non-responders should be 
evaluated in future trials.
As a general rule, a placebo effect should not be underestimated in clinical trials with 
a long follow up period. In order to obtain some insight into a placebo effect in a clinical 
trial with only 30 patients (chapter 5c) all patients were asked after 24 weeks by mail if 
they thought they received placebo or rituximab and the reason why they thought to 
have received the active drug or placebo. One patient did not respond and was therefore 
excluded from this analysis. Both study coordinators (physicians of the departments of 
rheumatology and oral and maxillofacial surgery), who regularly assessed the patients and 
who were blinded for the study medication, also guessed whether the patient had used 
rituximab or placebo. In 23 out of 29 patients estimation of treatment was correct for both 
physicians. The physicians correctly scored treatment modality of 25 and 26 patients out of 
the 29 patients, respectively (Tables 1 and 2).
In conclusion, both the blinded patients and doctors could quite accurately estimate if a 
patient received placebo or rituximab. Therefore, the placebo effect in this particular study 
is small which gives us an additional hint that rituximab is an effective treatment for SS.
Role of B cells
The classical view on the role of B cells in immunity is focused on the production of 
antibodies and autoantibodies in the case of autoimmune diseases. However, over the past 
years the role of B cells seems to have acquired much more dimensions such as regulating 
T cell subsets and dendritic cells through cytokine production, activation of T cells and 
antigen presentation to T cells.(13;14) As other autoimmune diseases, SS is long considered 
to be a T-lymphocyte mediated disease, however, in the light of these new developments 
the role of B cells might be more prominent than thought in the past. The promising results 
of B cell depletion therapy in SS also support the theory that there is a role for B cells in 
the pathogenesis of SS. E.g., cutaneous nodular amyloidosis in SS seems to be the result 
of a benign clonal proliferation of plasma cells in the skin that is part of the spectre of 
lymphoproliferative diseases associated with SS. Despite its rare occurrence, 16 cases of 
cutaneous amyloidosis have been reported in patients with SS, which is about 25% of the 
reported cases of cutaneous amyloidosis These cases and the description of the cases 
described in chapter 6 support the role of the B cell in SS.  
Future perspectives
Today, SS is diagnosed more and more in an early stage of the disease. Screening might 
become much easier if, in the future, e.g., the proteonomic profile can be used for diagnosis. 
Only one drop of saliva might be sufficient for diagnostics and/or treatment evaluation. 
Today no causal treatment is available, however, so far, the performed trials revealed that 
B cell depletion with rituximab is probably the most effective therapy available to date. Also 
our randomized double-blind placebo-controlled trial (chapter 5c) with rituximab treatment 
showed promising results. A trial investigating retreatment of all patients involved in that 
trial is in progress. Focus of that study will be a longer follow up period (64 weeks), the 
effect of retreatment and the effect of treatment in patients who have received initially 
a placebo. A histopathological study of parotid gland biopsies before and after rituximab 
treatment of the patients described in chapter 5c has also been initiated and hopefully 
confirms our clinical findings and the results of our pilot study on histopathological effects 







Besides the already performed phase II trials, larger phase III trials are needed before 
approval can be obtained for rituximab treatment in SS patients. In these larger phase III 
studies, additional attention should be paid to the long term side effects, possibility of 
retreatment, and the oral dose of prednisolone during the days after each infusion. We 
also like to pose that rituximab treatment is especially effective for patients with active 
disease, extraglandular manifestations and/or remaining salivary gland secretory potential. 
To confirm these hypotheses, in future larger trials less strict inclusion criteria related 
to baseline salivary gland function and a larger number of patients are needed. In order 
to define treatment protocols, criteria regarding responders/non-responders have to be 
implemented. Studies regarding disease activity scores are currently being performed and 
are also important for future treatment protocols.
In addition to phase III rituximab trials, also other types of B cell depletion therapies 
should be investigated including completely humanized anti-CD20, anti-CD22 and anti-
BAFF. To our opinion, there is a large role in the future for biologicals in the treatment of SS 
which could add substantially to a good quality if life of SS patients.
Table 2 Number of correct estimations. Maximum score is 3: patient and both physicians scored correct. 
Number of correct estimations 0 1 2 3
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